{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T04:58:21Z","timestamp":1772341101733,"version":"3.50.1"},"reference-count":56,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2022,4,22]],"date-time":"2022-04-22T00:00:00Z","timestamp":1650585600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Med."],"abstract":"<jats:sec>\n                    <jats:title>Background and Aim<\/jats:title>\n                    <jats:p>While considerable success has been achieved in the management of patients hospitalized with severe coronavirus disease 2019 (COVID-19), far less progress has been made with early outpatient treatment. We assessed whether the implementation of a home treatment algorithm\u2014designed based on a pathophysiologic and pharmacologic rationale\u2014and including non-steroidal anti-inflammatory drugs, especially relatively selective cyclooxygenase-2 inhibitors and, when needed, corticosteroids, anticoagulants, oxygen therapy and antibiotics\u2014at the very onset of mild COVID-19 symptoms could effectively reduce hospital admissions.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>This fully academic, matched-cohort study evaluated outcomes in 108 consecutive consenting patients with mild COVID-19, managed at home by their family doctors between January 2021 and May 2021, according to the proposed treatment algorithm and in 108 age-, sex-, and comorbidities-matched patients on other therapeutic schedules (ClinicalTrials.gov: NCT04854824). The primary outcome was COVID-19-related hospitalization. Analyses were by intention-to-treat.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      One (0.9%) patient in the \u201crecommended\u201d cohort and 12 (11.1%) in the \u201ccontrol\u201d cohort were admitted to hospital (\n                      <jats:italic>P<\/jats:italic>\n                      = 0.0136). The proposed algorithm reduced the cumulative length of hospital stays by 85% (from 141 to 19 days) as well as related costs (from \u20ac60.316 to \u20ac9.058). Only 9.8 patients needed to be treated with the recommended algorithm to prevent one hospitalization event. The rate of resolution of major symptoms was numerically\u2014but not significantly\u2014higher in the \u201crecommended\u201d than in the \u201ccontrol\u201d cohort (97.2 vs. 93.5%, respectively;\n                      <jats:italic>P<\/jats:italic>\n                      = 0.322). Other symptoms lingered in a smaller proportion of patients in the \u201crecommended\u201d than in the \u201ccontrol\u201d cohort (20.4 vs. 63.9%, respectively;\n                      <jats:italic>P<\/jats:italic>\n                      &amp;lt; 0.001), and for a shorter period.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>The adoption of the proposed outpatient treatment algorithm during the early, mild phase of COVID-19 reduced the incidence of subsequent hospitalization and related costs.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fmed.2022.785785","type":"journal-article","created":{"date-parts":[[2022,4,22]],"date-time":"2022-04-22T02:54:11Z","timestamp":1650596051000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":19,"title":["A Home-Treatment Algorithm Based on Anti-inflammatory Drugs to Prevent Hospitalization of Patients With Early COVID-19: A Matched-Cohort Study (COVER 2)"],"prefix":"10.3389","volume":"9","author":[{"given":"Elena","family":"Consolaro","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fredy","family":"Suter","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nadia","family":"Rubis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stefania","family":"Pedroni","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chiara","family":"Moroni","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elena","family":"Past\u00f2","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maria Vittoria","family":"Paganini","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Grazia","family":"Pravettoni","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Umberto","family":"Cantarelli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Norberto","family":"Perico","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Annalisa","family":"Perna","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tobia","family":"Peracchi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Piero","family":"Ruggenenti","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Giuseppe","family":"Remuzzi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2022,4,22]]},"reference":[{"key":"B1","unstructured":""},{"key":"B2","doi-asserted-by":"publisher","first-page":"243","DOI":"10.3390\/vaccines9030243","article-title":"Emerging SARS-CoV-2 variants and impact in global vaccination programs against SARS-CoV-2\/COVID-19","volume":"9","author":"G\u00f3mez","year":"2021","journal-title":"Vaccines."},{"key":"B3","doi-asserted-by":"publisher","first-page":"1017","DOI":"10.1038\/s41591-020-0968-3","article-title":"Extrapulmonary manifestations of COVID-19","volume":"26","author":"Gupta","year":"2020","journal-title":"Nat Med."},{"key":"B4","doi-asserted-by":"publisher","first-page":"1054","DOI":"10.1016\/S0140-6736(20)30566-3","article-title":"Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study","volume":"395","author":"Zhou","year":"2020","journal-title":"Lancet."},{"key":"B5","doi-asserted-by":"publisher","first-page":"603","DOI":"10.1001\/jama.2020.12603","article-title":"persistent symptoms in patients after acute COVID-19","volume":"324","author":"Carf\u00ec","year":"2020","journal-title":"JAMA."},{"key":"B6","doi-asserted-by":"publisher","first-page":"1292","DOI":"10.1001\/jama.2020.16747","article-title":"Corticosteroids in COVID-19 ARDS: evidence and hope during the pandemic","volume":"324","author":"Prescott","year":"2020","journal-title":"JAMA."},{"key":"B7","doi-asserted-by":"publisher","first-page":"1824","DOI":"10.1001\/jama.2020.6019","article-title":"Pharmacologic treatments for coronavirus disease 2019 (COVID-19): a review","volume":"323","author":"Sanders","year":"2020","journal-title":"JAMA."},{"key":"B8","doi-asserted-by":"publisher","first-page":"1330","DOI":"10.1001\/jama.2020.17023","article-title":"Association between administration of systemic corticosteroids and mortality among critically ill patients with COVID-19: a meta-analysis","volume":"324","author":"WHO Rapid Evidence Appraisal for COVID-19 Therapies (REACT) Working","year":"2020","journal-title":"JAMA."},{"key":"B9","doi-asserted-by":"publisher","first-page":"1412","DOI":"10.1126\/science.367.6485.1412","article-title":"Race to find COVID-19 treatments accelerates","volume":"367","author":"Kupferschmidt","year":"2020","journal-title":"Science."},{"key":"B10","doi-asserted-by":"publisher","first-page":"693","DOI":"10.1056\/NEJMoa2021436","article-title":"Dexamethasone in hospitalized patients with Covid-19","volume":"384","author":"RECOVERY Collaborative","year":"2021","journal-title":"N Engl J Med."},{"key":"B11","unstructured":"\u201cSolidarity\u201dClinical Trial for COVID-19 Treatments2020"},{"key":"B12","doi-asserted-by":"publisher","first-page":"2149","DOI":"10.1001\/jama.2020.22813","article-title":"Therapy for early COVID-19: a critical need","volume":"324","author":"Kim","year":"2020","journal-title":"JAMA."},{"key":"B13","unstructured":""},{"key":"B14","unstructured":""},{"key":"B15","doi-asserted-by":"publisher","first-page":"954","DOI":"10.1016\/j.cell.2020.04.013","article-title":"SnapShot: COVID-19","volume":"181","author":"Oberfeld","year":"2020","journal-title":"Cell."},{"key":"B16","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1038\/s41581-020-00357-4","article-title":"Immunity, endothelial injury and complement-induced coagulopathy in COVID-19","volume":"17","author":"Perico","year":"2021","journal-title":"Nat Rev Nephrol."},{"key":"B17","doi-asserted-by":"publisher","first-page":"1","DOI":"10.15761\/CMI.1000218","article-title":"A recurrent question from a primary care physician: how should I treat my COVID-19 patients at home?","volume":"5","author":"Suter","year":"2020"},{"key":"B18","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1016\/j.ijid.2020.09.1466","article-title":"COX2 inhibition in the treatment of COVID-19: review of literature to propose repositioning of celecoxib for randomized controlled studies","volume":"101","author":"Baghaki","year":"2020","journal-title":"Int J Infect Dis."},{"key":"B19","doi-asserted-by":"publisher","first-page":"469","DOI":"10.1002\/ddr.21794","article-title":"Targeting cyclooxygenase enzyme for the adjuvant COVID-19 therapy","volume":"82","author":"Prasher","year":"2021","journal-title":"Drug Dev Res."},{"key":"B20","doi-asserted-by":"publisher","first-page":"100941","DOI":"10.1016\/j.eclinm.2021.100941","article-title":"A simple, home-therapy algorithm to prevent hospitalisation for COVID-19 patients: a retrospective observational matched-cohort study","volume":"37","author":"Suter","year":"2021","journal-title":"EClinicalMedicine."},{"key":"B21","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1093\/ndt\/gfaa314","article-title":"Chronic kidney disease is a key risk factor for severe COVID-19: a call to action by the ERA-EDTA","volume":"36","author":"ERA-EDTA","year":"2021","journal-title":"Nephrol Dial Transplant."},{"key":"B22","doi-asserted-by":"publisher","first-page":"1345","DOI":"10.1001\/jamainternmed.2020.3539","article-title":"Risk factors associated with mortality among patients with COVID-19 in intensive care units in Lombardy, Italy","volume":"180","author":"Grasselli","year":"2020","journal-title":"JAMA Intern Med."},{"key":"B23","doi-asserted-by":"publisher","first-page":"705","DOI":"10.1038\/s41581-020-00349-4","article-title":"CKD is a key risk factor for COVID-19 mortality","volume":"16","author":"Gansevoort","year":"2020","journal-title":"Nat Rev Nephrol."},{"key":"B24","first-page":"165","article-title":"Performing a 1:N case-control match on propensity score","volume":"29","author":"Parsons","year":"2004","journal-title":"SAS SUGI."},{"key":"B25","doi-asserted-by":"publisher","first-page":"1701","DOI":"10.1111\/1475-6773.12182","article-title":"Methods for constructing and assessing propensity scores","volume":"49","author":"Garrido","year":"2014","journal-title":"Health Serv Res."},{"key":"B26","volume-title":"Clinical Trials: A Practical Approach","author":"Pocock","year":"1983"},{"key":"B27","doi-asserted-by":"publisher","first-page":"382","DOI":"10.1016\/j.medmal.2020.04.002","article-title":"Interleukin-6 as a potential biomarker of COVID-19 progression","volume":"50","author":"Ulhaq","year":"2020","journal-title":"Med Mal Infect."},{"key":"B28","doi-asserted-by":"publisher","first-page":"433","DOI":"10.1056\/NEJM200108093450607","article-title":"The coxibs, selective inhibitors of cyclooxygenase-2","volume":"345","author":"FitzGerald","year":"2001","journal-title":"N Engl J Med."},{"key":"B29","doi-asserted-by":"publisher","first-page":"e11610","DOI":"10.1371\/journal.pone.0011610","article-title":"Pharmacologic inhibition of COX-1 and COX-2 in influenza A viral infection in mice","volume":"5","author":"Carey","year":"2010","journal-title":"PLoS ONE."},{"key":"B30","doi-asserted-by":"publisher","first-page":"e1159","DOI":"10.1002\/cti2.1159","article-title":"Safety and potential efficacy of cyclooxygenase-2 inhibitors in coronavirus disease 2019","volume":"9","author":"Ong","year":"2020","journal-title":"Clin Transl Immunol."},{"key":"B31","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1016\/j.phrs.2016.02.020","article-title":"Acetaminophen from liver to brain: new insights into drug pharmacological action and toxicity","volume":"109","author":"Ghanem","year":"2016","journal-title":"Pharmacol Res."},{"key":"B32","doi-asserted-by":"publisher","first-page":"5704","DOI":"10.1002\/jmv.27158","article-title":"Paracetamol in the home treatment of early COVID-19 symptoms: a possible foe rather than a friend for elderly patients?","volume":"93","author":"Pandolfi","year":"2021","journal-title":"J Med Virol."},{"key":"B33","doi-asserted-by":"publisher","first-page":"579944","DOI":"10.3389\/fphar.2020.579944","article-title":"Paracetamol-induced glutathione consumption: is there a link with severe COVID-19 illness?","volume":"11","author":"Sestili","year":"2020","journal-title":"Front Pharmacol."},{"key":"B34","doi-asserted-by":"publisher","first-page":"769","DOI":"10.1016\/S0140-6736(13)60900-9","article-title":"Vascular and upper gastrointestinal effects of non-steroidal anti-inflammatory drugs: meta-analyses of individual participant data from randomised trials","volume":"382","year":"2013","journal-title":"Lancet."},{"key":"B35","doi-asserted-by":"publisher","first-page":"238","DOI":"10.1111\/bcp.12938","article-title":"Risk of acute and serious liver injury associated to nimesulide and other NSAIDs: data from drug-induced liver injury case-control study in Italy","volume":"82","author":"Donati","year":"2016","journal-title":"Br J Clin Pharmacol."},{"key":"B36","doi-asserted-by":"publisher","first-page":"e498","DOI":"10.1016\/S2665-9913(21)00104-1","article-title":"Non-steroidal anti-inflammatory drug use and outcomes of COVID-19 in the ISARIC Clinical Characterisation Protocol UK cohort: a matched, prospective cohort study","volume":"3","author":"Drake","year":"2021","journal-title":"Lancet Rheumatol."},{"key":"B37","doi-asserted-by":"publisher","first-page":"1259","DOI":"10.1016\/j.cmi.2020.06.003","article-title":"Ibuprofen use and clinical outcomes in COVID-19 patients","volume":"26","author":"Rinott","year":"2020","journal-title":"Clin Microbiol Infect."},{"key":"B38","doi-asserted-by":"publisher","first-page":"793","DOI":"10.1161\/01.CIR.100.8.793","article-title":"Increased proinflammatory cytokines in patients with chronic stable angina and their reduction by aspirin","volume":"100","author":"Ikonomidis","year":"1999","journal-title":"Circulation."},{"key":"B39","doi-asserted-by":"publisher","first-page":"930","DOI":"10.1213\/ANE.0000000000005292","article-title":"Aspirin use is associated with decreased mechanical ventilation, intensive care unit admission, and in-hospital mortality in hospitalized patients with coronavirus disease 2019","volume":"132","author":"Chow","year":"2021","journal-title":"Anesth Analg."},{"key":"B40","doi-asserted-by":"publisher","first-page":"1017","DOI":"10.1016\/S0531-5565(00)00128-5","article-title":"Interaction of indomethacin with cytokine production in whole blood. Potential mechanism for a brain-protective effect","volume":"35","author":"Bour","year":"2000","journal-title":"Exp Gerontol."},{"key":"B41","doi-asserted-by":"crossref","DOI":"10.22541\/au.161000568.81171409\/v1","article-title":"Efficacy and safety of indomethacin in Covid-19 patients","volume-title":"MedRxiv","author":"Ravichandran","year":"2021"},{"key":"B42","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1159\/000362724","article-title":"One hormone, two actions: anti- and pro-inflammatory effects of glucocorticoids","volume":"22","author":"Cruz-Topete","year":"2015","journal-title":"Neuroimmunomodulation."},{"key":"B43","doi-asserted-by":"publisher","first-page":"e343","DOI":"10.1371\/journal.pmed.0030343","article-title":"SARS: systematic review of treatment effects","volume":"3","author":"Stockman","year":"2006","journal-title":"PLoS Med."},{"key":"B44","doi-asserted-by":"publisher","first-page":"757","DOI":"10.1164\/rccm.201706-1172OC","article-title":"Corticosteroid Therapy for critically ill patients with middle east respiratory syndrome","volume":"197","author":"Arabi","year":"2018","journal-title":"Am J Respir Crit Care Med."},{"key":"B45","doi-asserted-by":"publisher","first-page":"n526","DOI":"10.1136\/bmj.n526","article-title":"A living WHO guideline on drugs to prevent covid-19","volume":"372","author":"Lamontagne","year":"2021","journal-title":"BMJ."},{"key":"B46","doi-asserted-by":"publisher","first-page":"1023","DOI":"10.3332\/ecancer.2020.1023","article-title":"COVID-19 and treatment with NSAIDs and corticosteroids: should we be limiting their use in the clinical setting?","volume":"14","author":"Russell","year":"2020","journal-title":"Ecancermedicalscience."},{"key":"B47","doi-asserted-by":"publisher","first-page":"388","DOI":"10.3390\/ijms18020388","article-title":"Pneumonia, acute respiratory distress syndrome, and early immune-modulator therapy","volume":"18","author":"Lee","year":"2017","journal-title":"Int J Mol Sci."},{"key":"B48","doi-asserted-by":"publisher","first-page":"763","DOI":"10.1016\/S2213-2600(21)00160-0","article-title":"Inhaled budesonide in the treatment of early COVID-19 (STOIC): a phase 2, open-label, randomised controlled trial","volume":"9","author":"Ramakrishnan","year":"2021","journal-title":"Lancet Respir Med."},{"key":"B49","doi-asserted-by":"publisher","first-page":"843","DOI":"10.1016\/S0140-6736(21)01744-X","article-title":"Inhaled budesonide for COVID-19 in people at high risk of complications in the community in the UK (PRINCIPLE): a randomised, controlled, open-label, adaptive platform trial","volume":"398","author":"Yu","year":"2021","journal-title":"Lancet."},{"key":"B50","doi-asserted-by":"publisher","first-page":"F1454","DOI":"10.1152\/ajprenal.00160.2020","article-title":"Is the kidney a target of SARS-CoV-2?","volume":"318","author":"Martinez-Rojas","year":"2020","journal-title":"Am J Physiol Renal Physiol."},{"key":"B51","doi-asserted-by":"publisher","first-page":"104362","DOI":"10.1016\/j.jcv.2020.104362","article-title":"Coagulation disorders in coronavirus infected patients: COVID-19, SARS-CoV-1, MERS-CoV andlessons from the past","volume":"127","author":"Giannis","year":"2020","journal-title":"J Clin Virol."},{"key":"B52","doi-asserted-by":"publisher","first-page":"790","DOI":"10.1056\/NEJMoa2105911","article-title":"Therapeutic anticoagulation with heparin in noncritically ill patients with Covid-19","volume":"385","author":"ATTACC","year":"2021","journal-title":"N Engl J Med."},{"key":"B53","doi-asserted-by":"publisher","first-page":"2459","DOI":"10.1093\/cid\/ciaa530","article-title":"Bacterial and fungal coinfection in individuals with coronavirus: a rapid review to support COVID-19 antimicrobial prescribing","volume":"71","author":"Rawson","year":"2020","journal-title":"Clin Infect Dis."},{"key":"B54","doi-asserted-by":"publisher","first-page":"915","DOI":"10.1093\/aje\/kwg231","article-title":"Evaluating medication effects outside of clinical trials: new-user designs","volume":"158","author":"Ray","year":"2003","journal-title":"Am J Epidemiol."},{"key":"B55","doi-asserted-by":"publisher","first-page":"e67","DOI":"10.1371\/journal.pmed.0050067","article-title":"Observational research, randomised trials, and two views of medical science","volume":"5","author":"Vandenbroucke","year":"2008","journal-title":"PLoS Med."},{"key":"B56","doi-asserted-by":"publisher","first-page":"1252","DOI":"10.7326\/M21-0878","article-title":"Prevalence of symptoms more than seven months after diagnosis of symptomatic COVID-19 in an outpatient setting","volume":"174","author":"Nehme","year":"2021","journal-title":"Ann Intern Med."}],"container-title":["Frontiers in Medicine"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2022.785785\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,4,22]],"date-time":"2022-04-22T02:54:15Z","timestamp":1650596055000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2022.785785\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,4,22]]},"references-count":56,"alternative-id":["10.3389\/fmed.2022.785785"],"URL":"https:\/\/doi.org\/10.3389\/fmed.2022.785785","relation":{"has-preprint":[{"id-type":"doi","id":"10.1101\/2021.09.29.21264298","asserted-by":"object"}]},"ISSN":["2296-858X"],"issn-type":[{"value":"2296-858X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,4,22]]},"article-number":"785785"}}